0001723805-17-000001.txt : 20171129 0001723805-17-000001.hdr.sgml : 20171129 20171128173705 ACCESSION NUMBER: 0001723805-17-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171129 DATE AS OF CHANGE: 20171128 EFFECTIVENESS DATE: 20171129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chase Therapeutics Corp CENTRAL INDEX KEY: 0001723805 IRS NUMBER: 815113723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-299627 FILM NUMBER: 171226286 BUSINESS ADDRESS: STREET 1: 1825 K STREET NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 202-223-7002 MAIL ADDRESS: STREET 1: 1825 K STREET NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 D 1 primary_doc.xml X0708 D LIVE 0001723805 Chase Therapeutics Corp 1825 K STREET NW SUITE 520 WASHINGTON DC DISTRICT OF COLUMBIA 20006 202-223-7002 DELAWARE None None Corporation true 2017 Thomas N. Chase c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Executive Officer Director President and Chief Executive Officer Kathleen Clarence-Smith c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Director Richard P. Dulik c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 520 Washington DC DISTRICT OF COLUMBIA 20006 Executive Officer Secretary Pharmaceuticals Decline to Disclose 06b false 2017-11-17 false true false 1 1300000 1300000 0 This filing covers the sale and issuance of Series A-1 Preferred Stock and the underlying Common Stock issuable upon conversion thereof. false 1 0 0 0 false Chase Therapeutics Corp /s/ Thomoas N. Chase Thomas N. Chase President and CEO 2017-11-21